Scott Sweet, senior managing partner of IPO Boutique, was quoted in the Boston.com on Saturday:
With the stock market hitting new highs, investors want to take chances they might not otherwise take in a flat or down market, said Scott Sweet, senior managing partner at IPO Boutique, which researches and invests in IPOs.
The full article is available here: http://www.boston.com/business/technology/2013/09/20/burst-ipos-follows-gains-stock-market/ychPGj6w5Prrtco5uvR17O/story.html
Scott offers research packages for upcoming IPOs at IPO Boutique.
The same research information is also available on a global scale at IPO Global Research.
Thursday, September 26, 2013
Friday, September 20, 2013
IPOs 2013: RE/MAX
IPO RE/MAX (RMAX) is a franchisor of real estate brokerage services. Their franchisees operate under the RE/MAX brand name, which has has the highest level of unaided brand awareness in real estate in the U.S. and Canada according to a 2013 survey by MMR Strategy Group. The majority of RE/MAX's revenue is derived from fixed, contractual fees and dues based on the number of agents in their franchise network.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Monday, September 16, 2013
IPOs 2013: Rocket Fuel
IPO Rocket Fuel (FUEL) is a technology company that utilizes an Artificial Intelligence and Big Data-driven predictive modeling and automated decision-making platform to address the needs of digital advertising markets. Their AI system autonomously purchases ad spots to create portfolios of impressions designed to optimize the goals of their advertisers. Rocket Fuel has successfully run advertising campaigns for products and brands ranging from consumer products to luxury automobiles to travel.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Friday, September 13, 2013
IPOs 2013: Five Prime
IPO Five Prime Therapeutics (FPRX) is a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics. Protein therapeutics are antibodies or drugs that block disease processes, including cancer and inflammatory diseases. Five Prime has developed a library of more than 5,600 human extracellular proteins, and use their proprietary screening technologies to identify new targets for protein therapeutics.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Thursday, September 12, 2013
IPOs 2013: Bind Therapeutics
IPO Bind Therapeutics Inc (BIND) is a clinical-stage nanomedicine platform company developing Accurins. Accurins are programmable therapeutics designed to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Wednesday, September 11, 2013
IPOs 2013: FireEye
IPO FireEye (FEYE) provides real-time protection against cyber attacks to enterprises and governments worldwide. Their proprietary virtual machine-based technology represents a new approach to detecting cyber attacks in real time while scaling in response to increasing network performance requirements.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Tuesday, September 10, 2013
IPOs 2013: Acceleron
IPO Acceleron Pharma (XLRN) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. Their research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, key regulators in the growth and repair of tissues throughout the human body. Acceleron has three internally discovered protein therapeutic candidates that are currently being studied in 12 ongoing Phase 2 clinical trials.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Friday, September 6, 2013
IPOs 2013: Benefitfocus
IPO Benefitfocus (BNFT) is a provider of cloud-based benefits software solutions for consumers, employers, insurance carriers, and brokers. The Benefitfocus platform provides an integrated suite of solutions that enables customers (which are employers and insurance carriers) to shop, enroll, manage, and exchange benefits information. Benefitfocus's comprehensive solutions support core benefits plans, including healthcare, dental, life, and disability insurance, and voluntary benefits plans, such as critical illness, supplemental income, and wellness programs.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Wednesday, September 4, 2013
IPOs 2013: Potbelly Corporation
IPO Potbelly Corporation (PBPB) is a neighborhood sandwich concept offering warm sandwiches, salads and other fresh menu items. Sandwiches, salads and hand-dipped milkshakes are made fresh to order and cookies are baked fresh each day. As of June 30, 2013, Potbelly had a domestic base of 286 shops in 18 states and the District of Columbia. In addition, there are 12 franchised shops in the Middle East.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
Subscribe to:
Comments (Atom)